Key Points
- Insider sale: BioCryst insider Alane Barnes sold 91,004 shares at an average price of $7.10 for a total of $646,128.40, cutting her stake by 17.94% to 416,152 shares — the trade was disclosed in an SEC Form 4.
- Financials and market reaction: BioCryst reported Q results with EPS of $0.06 (missing the $0.07 estimate) and revenue of $159.4M (versus $162.9M forecast), yet the stock rose about 9.6% to $7.85; analysts remain mixed but the consensus rating is "Moderate Buy" with a $19.33 target.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 19,770 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $7.65, for a total transaction of $151,240.50. Following the completion of the transaction, the insider directly owned 345,476 shares of the company's stock, valued at approximately $2,642,891.40. The trade was a 5.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
BioCryst Pharmaceuticals Stock Performance
NASDAQ BCRX opened at $7.85 on Thursday. The firm's fifty day moving average price is $7.12 and its two-hundred day moving average price is $8.37. The stock has a market cap of $1.65 billion, a PE ratio of -157.00 and a beta of 0.91. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.31.
BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.01). The firm had revenue of $159.40 million for the quarter, compared to analyst estimates of $162.91 million. BioCryst Pharmaceuticals had a negative net margin of 1.46% and a negative return on equity of 4.24%. The company's revenue was up 36.1% compared to the same quarter last year. During the same period last year, the business earned ($0.07) EPS. As a group, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the stock. JMP Securities lifted their target price on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a "market outperform" rating in a research report on Wednesday, October 15th. Needham & Company LLC reduced their price objective on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, November 4th. Evercore ISI restated an "in-line" rating and issued a $8.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. Barclays lowered their target price on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an "equal weight" rating for the company in a research report on Tuesday, November 4th. Finally, Cantor Fitzgerald upped their price target on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an "overweight" rating in a research report on Wednesday, October 15th. Ten investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $19.33.
View Our Latest Analysis on BCRX
Hedge Funds Weigh In On BioCryst Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the company. Headlands Technologies LLC acquired a new position in BioCryst Pharmaceuticals in the first quarter valued at $32,000. New Age Alpha Advisors LLC acquired a new stake in BioCryst Pharmaceuticals during the first quarter worth approximately $62,000. Family Legacy Financial Solutions LLC bought a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter worth approximately $72,000. Focus Partners Wealth bought a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at $77,000. Finally, Farther Finance Advisors LLC lifted its position in shares of BioCryst Pharmaceuticals by 326.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 8,109 shares during the period. Institutional investors own 85.88% of the company's stock.
BioCryst Pharmaceuticals Company Profile
(
Get Free Report)
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
